Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up

Table 2 Changes in the BCVA and CRT from baseline after IVR treatment in all AMD, tAMD and PCV patients

	1 Month		P value*	3 Months		P value*	6 Months		P value*	12 Months		P value*
Change in BCVA	Mean	Median (IQR)		Mean	Median (IQR)		Mean	Median (IQR)		Mean	Median (IQR)
total	−0.03	0.00 (-0.12 - 0.00)	0.12	−0.11	−0.12 ( -0.24 - 0.00)	<0.001	−0.10	−0.12 ( -0.24 - 0.00)	0.001	−0.09	−0.12 (-0.30 - 0.00)	0.02
tAMD	−0.06	0.00 (-0.17 - 0.00)	0.01	−0.17	−0.20 (-0.30 - -0.05)	<0.001	−0.15	−0.18 (-0.30 - -0.05)	0.006	−0.16	−0.18 (-0.30 - -0.05)	0.01
PCV	0.00	0.00 (-0.10 - 0.00)	0.73	−0.06	−0.07(-0.22 - 0.00)	0.08	−0.06	−0.04 (-0.18 - 0.00)	0.08	−0.04	−0.05 (-0.24 - 0.10)	0.33
Change in CRT	Mean	Median (IQR)		Mean	Median (IQR)		Mean	Median (IQR)		Mean	Median (IQR)
total	−104	−74 (-142 - -25)	< 0.001	−132	−119 (-170 - -47)	< 0.001	−95	−53 (-126 - -28)	< 0.001	−94	−80 (-140 - -40)	< 0.001
tAMD	−112	−72 (-147 - -29)	< 0.001	−144	−93 (-191 - -72)	< 0.001	−120	−52 (-154 - -32)	< 0.001	−137	−97 (-197 - -52)	< 0.001
PCV	−98	−107 (-142 - -25)	< 0.001	−121	−128 (-170 - -45)	< 0.001	−74	−55 (-119 - -28)	< 0.001	−94	−71 (-133 - -33)	< 0.001

BCVA, Best corrected visual acuity (LogMAR); CRT, Central retinal thickness; IQR, Interquartile range.
*Wilcoxon signed rank test (comparison with baseline).

ISSN: 1471-2415